Samsung Biologics Launches $1.8 Billion Bid for PolyPeptide
The Spin
Narrative A
Samsung Biologics' acquisition of PolyPeptide will position the combined company as the dominant force in peptide-based drug manufacturing. PolyPeptide's 70-plus years of API heritage and booming GLP-1 pipeline — revenue up 41.6% in H1 2026 — make this a strategically sound deal at a 40% premium. This large-scale, bold investment will accelerate the delivery of life-saving therapeutics to market.
Narrative B
The peptide industry's explosive growth is built on hype far outpacing hard science, with most trendy compounds entering the market without rigorous trials. Consumers, therefore, are injecting unregulated peptides with no guarantee of safety or long-term effects. As a result, pouring billions into scaling up peptide manufacturing before the evidence base catches up puts profits before patient protection.